A phase 1, escalating dose study of CT-322 [Adnectin; Adnexus], a VEGFR-2 [vascular endothelial growth factor receptor-2] antagonist, as monotherapy in patients with advanced solid tumours and non-Hodgkin's lymphoma

Trial Profile

A phase 1, escalating dose study of CT-322 [Adnectin; Adnexus], a VEGFR-2 [vascular endothelial growth factor receptor-2] antagonist, as monotherapy in patients with advanced solid tumours and non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Pegdinetanib (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Oct 2009 Actual patient number (40) added as reported by ClinicalTrials.gov.
    • 23 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 08 Apr 2008 The expected completion date for this trial is now 1 Jul 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top